The investigators will conduct a hybrid type 1 effectiveness implementation trial to assess the effectiveness of acupuncture and guided relaxation on 360 people with Sickle Cell Disease (SCD), while observing and gathering information on implementation in three health systems: University of Illinois Hospital \& Health Sciences System, University of Florida Health, and Duke University Health Systems. Each serves a large population with SCD, uses EPIC as their electronic health record, and has a Clinical and Translational Science Award (CTSA), which will help speed the translation of discovery into improved patient care. During the UH3 Implementation Phase, the 3-arm, 3-site randomized controlled trial will follow a quantitative modified SMART design, a pragmatic trial that evaluates adaptive interventions where the guided relaxation and acupuncture interventions respond to patients' characteristics and evolving pain status. The investigators rely on the Consolidated Framework for Implementation Research (CFIR) to plan, execute, and evaluate associated implementation processes. The use of complementary and integrative health (CIH) therapies by those with SCD to reduce pain and opioid use, to help enable them to better cope with their pain, is well known, but there are few studies that evaluate the effectiveness of these therapies, and none that also evaluates the implementation across multiple health care systems and patient populations as this study will. Aim 1: Determine the effectiveness of guided relaxation and acupuncture as compared to usual care in decreasing pain and opioid use for SCD patients. Hypothesis: At 6-weeks, SCD patients randomized to either CIH intervention will have a greater decrease in pain, opioid use, sleep, anxiety, depressive symptoms, and pain catastrophizing compared to SCD patients randomized to usual care. Aim 2: Identify the best adaptive intervention for improved outcomes by documenting outcomes among adaptive intervention sequences: (1) initiate guided relaxation and switch to acupuncture for non-responders at midpoint; (2) initiate guided relaxation and continue with guided relaxation for non-responders at midpoint; (3) initiate acupuncture and switch to guided relaxation for non-responders at midpoint or (4) initiate acupuncture and continue with acupuncture for non-responders at midpoint. Aim 3: Explore differences in response to the adaptive interventions by age and sex. Aim 4: Identify implementation facilitators, challenges, and solutions for structures and processes that contribute to the seamless integration of CIH therapies into the 3 health systems by conducting individual interviews with participants in the intervention group who responded to the intervention and those who did not. The investigators will also conduct focus groups with hospital personnel at 4 timepoints.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
379
Guided relaxation uses the mind to reduce pain, promote well-being, and improve physical function. Guided relaxation is a state of concentration and focused attention that gives people more control over their pain experience and its impact and an increased sense of well-being.
Acupuncture is a body-based therapy that includes the insertion of thin needles at strategic points on the body that has been proven effective for reducing pain.
University of Florida
Gainesville, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Illinois at Chicago
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Duke University
Durham, North Carolina, United States
PROMIS Pain Interference
Scores range from 4-20; higher scores indicate that pain is interfering with daily activities more
Time frame: From Baseline to 24 weeks
Pain, Enjoyment of Life and General Activity scale (PEG)
0-10 rating on pain intensity, enjoyment of life and general activity
Time frame: From Baseline to 24 weeks
PROMIS Physical Function
4-20 rating on the impact of pain on ability to perform normal activities; higher scores indicate greater impact of pain on physical function
Time frame: From Baseline to 24 weeks
Generalised Anxiety Disorder Questionnaire (GAD-7)
Measure of Anxiety with scores ranging from 0-21. Higher scores indicate higher levels of anxiety.
Time frame: From Baseline to 24 weeks
Patient Health Questionnaire Depression Scale (PHQ)
0-24 rating of depression. 10 or greater total is considered major depression, 20 or more is severe major depression.
Time frame: From Baseline to 24 weeks
PROMIS sleep disturbance 8a
8-40 rating with higher scores indicating greater severity of sleep disturbance
Time frame: From Baseline to 24 weeks
Sleep duration
Hours a participant has slept
Time frame: From Baseline to 24 weeks
Pain Catastrophizing Scale (PCS)
0-52 scale with higher scores indicating more catastrophizing thoughts are present
Time frame: From Baseline to 24 weeks
Patient's Global Impression of Change (PGIC)
1-7 scale with higher scores indicating more improvement in pain from the patient's perspective
Time frame: From Baseline to 24 weeks
Tobacco, Alcohol, Prescription medication, and other Substance use (TAPS1)
1-20 scale with higher score relating to more frequent substance use over the past 12 months
Time frame: From Baseline to 24 weeks
Gastrointestinal Constipation 9a
9-45 scale with higher scores indicating more severe constipation symptoms
Time frame: From Baseline to 24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.